#United States #New York #Zepbound #Eli Lilly #Ro

Revolutionizing Access to Obesity Treatment

In a significant move to enhance healthcare for individuals battling obesity, Ro is collaborating with Eli Lilly and Company to facilitate smoother access to Zepbound® (tirzepatide) single-dose vials. This partnership aims to streamline the experience for Ro patients seeking effective and affordable obesity treatment via the LillyDirect® self-pay pharmacy channel.

The Importance of Zepbound® in Obesity Management

Obesity is a complex health issue that can lead to numerous complications, including diabetes and heart disease. Recognizing the urgent need for effective treatment options, Eli Lilly developed Zepbound®, a dual GIP and GLP-1 receptor agonist that has undergone rigorous testing and received FDA approval. It is particularly noteworthy that Zepbound is touted as the most affordable branded incretin medication available to patients, thus offering a reliable option for those seeking help in managing their weight.

The Role of Ro

Ro, a pioneer in direct-to-patient healthcare since 2017, has been instrumental in providing tailored support to individuals on their weight management journeys. The company’s commitment to accessibility means that patients can now receive Zepbound® prescriptions from Ro-affiliated providers seamlessly through the Ro app.

This collaboration not only simplifies the process of obtaining necessary medications but also eliminates significant barriers that often hinder access to care. As Patrik Jonsson, executive vice president at Lilly Cardiometabolic Health, articulated, this integration will enhance the availability of effective obesity treatments by providing a streamlined experience for patients.

How Will This Work?

Patients will benefit from a fully integrated platform that guides them through the entire healthcare experience—from initial diagnosis to the delivery of their medications. Ro’s all-encompassing model includes ongoing care management, treatment adherence, and personalized support, ensuring that patients receive comprehensive assistance throughout their journey.

Zach Reitano, Ro's co-founder and CEO, emphasized the groundbreaking nature of offering Zepbound® vials through LillyDirect®. He stated, "This integration further streamlines access to the only approved dual GIP and GLP-1 receptor agonist without dismissing the patient experience or requiring them to leave their homes."

Ongoing Patient Support

Since its inception, Ro has provided countless patients with methods to engage in effective weight management. Their services encompass a plethora of support systems, including:

• - A licensed physician's guidance
• - 24/7 messaging and communication
• - One-on-one coaching tailored for individual needs
• - Educational materials to empower informed decisions
• - Regular monitoring for side effects and necessary adjustments in dosage

By employing advanced, proprietary data analysis, Ro assists patients in identifying the most suitable medication choices at optimal prices, whether this involves utilizing their insurance benefits or opting for self-pay.

For patients eager to access Zepbound® single-dose vials, they can begin their journey at Ro's dedicated webpage, making it simpler than ever to prioritize their health.

About Ro

Ro is a trailblazer in the direct-to-patient healthcare arena, dedicated to overcoming the obstacles that patients face in accessing effective care. Their comprehensive, vertically integrated services enable a truly effective healthcare experience—streamlining everything from diagnosis through to medication delivery and long-term care. With a commitment to supporting every patient across the nation, Ro continues to expand its reach and impact, catering especially to those in primary care deserts.

This collaboration with Eli Lilly represents a promising advancement in obesity care, affirming Ro’s mission to make healthcare easy and effective for everyone seeking to reclaim their health.